{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-092830","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.642183+00:00","generated_at":"2026-05-31T11:51:56.677361+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Janux Q2 2024 net loss $6.0M; cash $646.3M; receives $7.5M Merck milestone","bullets":["Net loss of $6.0M vs $17.5M in Q2 2023; improvement driven by $7.5M milestone payment from Merck.","Cash and investments $646.3M at June 30, 2024, up from $344.0M at Dec 31, 2023.","R&D expense flat at $14.9M; G&A expense $7.8M vs $6.9M in prior year.","Enrollment ongoing for JANX007 (PSMA) and JANX008 (EGFR) trials; JANX007 data update expected 2H 2024.","Appointed Eric Dobmeier and Natasha Hernday to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-092830","json":"https://secwatch.observer/filing/0000950170-24-092830.json","markdown":"https://secwatch.observer/filing/0000950170-24-092830.md","text":"https://secwatch.observer/filing/0000950170-24-092830.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000095017024092830/0000950170-24-092830-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000095017024092830/janx-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:51:56.677361+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}